Chong Kun Dang (CEO Kim Young-joo) begins the development of new anti-cancer drugs by introducing antibody-drug combination (ADC) technology.
On the 3rd, Chong Kun Dang signed a contract to introduce antibody-drug combination technology with Synaffix BV, a Dutch biotech company. The contract size is USD 132 million (about KRW 165 billion), including the down payment, development, licenses, and sales milestones, and royalties for each stage of sales after commercialization are set separately.
With this contract, Chong Kun Dang intends to secure the right to use Synapix’s three combined antibody-drug platform technologies, GlycoConnect™, HydraSpace™, and toxSYN™, and begin the development of ADC anticancer drugs in earnest.
Chong Kun Dang CEO Kim Young-joo said, “Chong Kun Dang builds expertise and know-how by developing various anti-cancer drugs, such as the small cell lung cancer drug Calmtobel and the anti-cancer tubular antibody CKD- 702 “We will speed up the development,” he said.
Peter van de Sande, CEO of Synapix, said, “We are pleased to have Synapix’s new antibody-drug combination technology included in the pipeline from Chong Kun Dang, which has outstanding capabilities in the field of anticancer drugs.” We intend to remain close. and long-term collaboration so we can develop breakthrough anti-cancer drugs that patients need.”
Synapix’s ADC platform technology is a next-generation technology that can realize site-specific conjugation where a precise number of drugs are conjugated to an antibody at a precise location. While other technologies require antibody modification, Synapix’s technology can apply previously discovered antibodies as unmodified ADCs, enabling safe and efficient production from toxicity while possessing higher efficacy than existing ADCs.
Since 2019, Chong Kun Dang has been conducting joint research with Synapix to discover competitive ADCs, ensuring ADCs with higher efficacy and safety compared to existing ADCs.
